Page 1933 - Williams Hematology ( PDFDrive )

1908 Part XII: Hemostasis and Thrombosis Chapter 112: Platelet Morphology, Biochemistry, and Function 1909

1455. Weber AA, Zimmermann KC, Meyer-Kirchrath J, Schrör K: Cyclooxygenase-2 in 1487. Zhang C, et al: High-resolution crystal structure of human protease-activated recep-
human platelets as a possible factor in aspirin resistance. Lancet 353(9156):900, 1999. tor 1. Nature 492(7429):387–392, 2012.
1456. Funk CD, FitzGerald GA: COX-2 inhibitors and cardiovascular risk. J Cardiovasc 1488. Ishihara H, et al: Antibodies to protease-activated receptor 3 inhibit activation of
Pharmacol 50(5):470–479, 2007. mouse platelets by thrombin. Blood 91(11):4152–4157, 1998.
1457. Parent JL, et al: Internalization of the TXA2 receptor alpha and beta isoforms. Role of 1489. Kahn ML, et al: A dual thrombin receptor system for platelet activation. Nature
the differentially spliced COOH terminus in agonist-promoted receptor internaliza- 394(6694):690–694, 1998.
tion. J Biol Chem 274(13):8941–8948, 1999. 1490. Kahn ML, et al: Protease-activated receptors 1 and 4 mediate activation of human
1458. Habib A, FitzGerald GA, Maclouf J: Phosphorylation of the thromboxane recep- platelets by thrombin. J Clin Invest 103(6):879–887, 1999.
tor alpha, the predominant isoform expressed in human platelets. J Biol Chem 1491. Andrade-Gordon P, et al: Design, synthesis, and biological characterization of a
274(5):2645–2651, 1999. peptide-mimetic antagonist for a tethered-ligand receptor. Proc Natl Acad Sci U S A
1459. Kim SO, et al: Purification of the human blood platelet thromboxane A2/prostaglan- 96(22):12257–12262, 1999.
din H2 receptor protein. Biochem Pharmacol 43(2):313–322, 1992. 1492. Covic L, Gresser AL, Kuliopulos A: Biphasic kinetics of activation and signaling for
1460. Ushikubi F, et al: Purification of the thromboxane A2/prostaglandin H2 receptor from PAR1 and PAR4 thrombin receptors in platelets. Biochemistry 39(18):5458–5467,
human blood platelets. J Biol Chem 264(28):16496–16501, 1989. 2000.
1461. Takahara K, et al: The response to thromboxane A2 analogues in human platelets. 1493. Shapiro MJ, et al: Protease-activated receptors 1 and 4 are shut off with distinct kinet-
Discrimination of two binding sites linked to distinct effector systems. J Biol Chem ics after activation by thrombin. J Biol Chem 275(33):25216–25221, 2000.
265(12):6836–6844, 1990. 1494. Sambrano GR, et al: Role of thrombin signalling in platelets in haemostasis and
1462. Thomas DW, et al: Coagulation defects and altered hemodynamic responses in mice thrombosis. Nature 413(6851):74–78, 2001.
lacking receptors for thromboxane A2. J Clin Invest 102(11):1994–2001, 1998. 1495. Nakanishi-Matsui M, et al: PAR3 is a cofactor for PAR4 activation by thrombin.
1463. Gabbeta J, et al: Platelet signal transduction defect with Ga subunit dysfunction and Nature 404(6778):609–613, 2000.
diminished Gaq in a patient with abnormal platelet responses. Proc Natl Acad Sci 1496. Weiss EJ, et al: Protection against thrombosis in mice lacking PAR3. Blood
U S A 94(16):8750–8755, 1997. 100(9):3240–3244, 2002.
1464. Allan CJ, et al: Characterization of the cloned HEL cell thromboxane A2 receptor: 1497. Hoxie JA, et al: Internalization and recycling of activated thrombin receptors. J Biol
Evidence that the affinity state can be altered by G alpha 13 and G alpha q. J Pharmacol Chem 268(18):13756–13763, 1993.
Exp Ther 277(2):1132–1139, 1996. 1498. Trejo J, Coughlin SR: The cytoplasmic tails of protease-activated receptor-1 and
1465. Djellas Y, et al: Identification of Galpha13 as one of the G-proteins that couple to substance P receptor specify sorting to lysosomes versus recycling. J Biol Chem
human platelet thromboxane A2 receptors. J Biol Chem 274(20):14325–14330, 1999. 274(4):2216–2224, 1999.
1466. Nakahata N, et al: Gq/11 communicates with thromboxane A2 receptors in human 1499. Antoniak S, et al: PAR-1 contributes to the innate immune response during viral
astrocytoma cells, rabbit astrocytes and human platelets. Res Commun Mol Pathol infection. J Clin Invest 123(3):1310–1322, 2013.
Pharmacol 87(3):243–251, 1995. 1500. Khoufache K, et al: PAR1 contributes to influenza A virus pathogenicity in mice. J Clin
1467. Paul BZ, Jin J, Kunapuli SP: Molecular mechanism of thromboxane A(2)-induced Invest 123(1):206–214, 2013.
platelet aggregation. Essential role for p2t(ac) and alpha(2a) receptors. J Biol Chem 1501. Berri F, et al: Switch from protective to adverse inflammation during influenza: Viral
274(41):29108–29114, 1999. determinants and hemostasis are caught as culprits. Cell Mol Life Sci 71(5):885–898, 2014.
1468. Ushikubi F, Nakamura K, Narumiya S: Functional reconstitution of platelet throm- 1502. Ruggeri ZM, et al: Unravelling the mechanism and significance of thrombin binding
boxane A2 receptors with Gq and Gi2 in phospholipid vesicles. Mol Pharmacol to platelet glycoprotein Ib. Thromb Haemost 104(5):894–902, 2010.
46(5):808–816, 1994. 1503. Celikel R, et al: Modulation of alpha-thrombin function by distinct interactions with
1469. Dorsam RT, et al: Coordinated signaling through both G12/13 and G(i) pathways is suf- platelet glycoprotein Ibalpha. Science 301(5630):218–221, 2003.
ficient to activate GPIIb/IIIa in human platelets. J Biol Chem 277(49):47588–47595, 2002. 1504. Dumas JJ, et al: Crystal structure of the GpIbalpha-thrombin complex essential for
1470. Klages B, et al: Activation of G12/G13 results in shape change and Rho/Rho- platelet aggregation. Science 301(5630):222–226, 2003.
kinase-mediated myosin light chain phosphorylation in mouse platelets. J Cell Biol 1505. Lova P, et al: Thrombin induces platelet activation in the absence of functional
144(4):745–754, 1999. protease activated receptors 1 and 4 and glycoprotein Ib-IX-V. Cell Signal 22(11):
1471. Nieswandt B, et al: Costimulation of Gi- and G12/G13-mediated signaling path- 1681–1687, 2010.
ways induces integrin alpha IIbbeta 3 activation in platelets. J Biol Chem 277(42): 1506. Gibbins JM: Tweaking the gain on platelet regulation: The tachykinin connection.
39493–39498, 2002. Atherosclerosis 2008.
1472. Pulcinelli FM, et al: Protein kinase C activation is not a key step in ADP-mediated 1507. Graham GJ, et al: Tachykinins regulate the function of platelets. Blood 104(4):
exposure of fibrinogen receptors on human platelets. FEBS Lett 364(1):87–90, 1995. 1058–1065, 2004.
1473. Knezevic I, Dieter JP, Le Breton GC: Mechanism of inositol 1,4,5-trisphosphate- 1508. Gleissner CA, von HP, Ley K: Platelet chemokines in vascular disease. Arterioscler
induced aggregation in saponin-permeabilized platelets. J Pharmacol Exp Ther Thromb Vasc Biol 28(11):1920–1927, 2008.
260(3):947–955, 1992. 1509. McIntyre TM, Zimmerman GA, Prescott SM: Biologically active oxidized phospho-
1474. Nugteren DH: Arachidonate lipoxygenase in blood platelets. Biochim Biophys Acta lipids. J Biol Chem 274(36):25189–25192, 1999.
380(2):299–307, 1975. 1510. Honda Z, et al: Cloning by functional expression of platelet-activating factor receptor
1475. Johnson EN, Brass LF, Funk CD: Increased platelet sensitivity to ADP in mice lacking from guinea-pig lung. Nature 349(6307):342–346, 1991.
platelet-type 12-lipoxygenase. Proc Natl Acad Sci U S A 95(6):3100–3105, 1998. 1511. Nakamura M, et al: Molecular cloning and expression of platelet-activating factor
1476. Coffey MJ, et al: Platelet 12-lipoxygenase activation via glycoprotein VI: Involvement receptor from human leukocytes. J Biol Chem 266(30):20400–20405, 1991.
of multiple signaling pathways in agonist control of H(P)ETE synthesis. Circ Res 1512. Carlson SA, Chatterjee TK, Fisher RA: The third intracellular domain of the plate-
94(12):1598–1605, 2004. let-activating factor receptor is a critical determinant in receptor coupling to phos-
1477. Dasari VR, Jin J, Kunapuli SP: Distribution of leukotriene B4 receptors in human phoinositide phospholipase C-activating G proteins. Studies using intracellular
hematopoietic cells. Immunopharmacology 48(2):157–163, 2000. domain minigenes and receptor chimeras. J Biol Chem 271(38):23146–23153, 1996.
1478. Maclouf JA, Murphy RC: Transcellular metabolism of neutrophil-derived leukotriene 1513. Chao W, et al: Protein tyrosine phosphorylation and regulation of the receptor for
A4 by human platelets. A potential cellular source of leukotriene C4. J Biol Chem platelet-activating factor in rat Kupffer cells. Effect of sodium vanadate. Biochem J
263(1):174–181, 1988. 288(Pt 3):777–784, 1992.
1479. Maugeri N, et al: Polymorphonuclear leukocyte-platelet interaction: Role of P- 1514. Stafforini DM: Biology of platelet-activating factor acetylhydrolase (PAF-AH, lipopro-
selectin in thromboxane B2 and leukotriene C4 cooperative synthesis. Thromb Hae- tein associated phospholipase A2). Cardiovasc Drugs Ther 23(1):73–83, 2009.
most 72(3):450–456, 1994. 1515. Eitzman DT, et al: Hyperlipidemia promotes thrombosis after injury to atheroscle-
1480. Levy BD, et al: Agonist-induced lipoxin A4 generation: Detection by a novel lipoxin rotic vessels in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 20(7):
A4-ELISA. Lipids 28(12):1047–1053, 1993. 1831–1834, 2000.
1481. Ofosu FA, Liu L, Freedman J: Control mechanisms in thrombin generation. Semin 1516. Sano T, et al: Multiple mechanisms linked to platelet activation result in lyso-
Thromb Hemost 22(4):303–308, 1996. phosphatidic acid and sphingosine 1-phosphate generation in blood. J Biol Chem
1482. Phillips DR: Thrombin interaction with human platelets. Potentiation of thrombin- 277(24):21197–21206, 2002.
induced aggregation and release by inactivated thrombin. Thromb Diath Haemorrh 1517. Smyth SS, et al: Roles of lysophosphatidic acid in cardiovascular physiology and dis-
32(1):207–215, 1974. ease. Biochim Biophys Acta 1781(9):563–570, 2008.
1483. Bahou W: Thrombin receptors, in Platelets, edited by AD Michelson, pp 179–200. 1518. Umezu-Goto M, et al: Autotaxin has lysophospholipase D activity leading to tumor
Academic Press, San Diego, 2007. cell growth and motility by lysophosphatidic acid production. J Cell Biol 158(2):
1484. Hung DT, et al: Cloned platelet thrombin receptor is necessary for thrombin-induced 227–233, 2002.
platelet activation. J Clin Invest 89(4):1350–1353, 1992. 1519. Leblanc R, et al: Interaction of platelet-derived autotaxin with tumor integrin
1485. Furman MI, et al: The cleaved peptide of the thrombin receptor is a strong platelet alphaVbeta3 controls metastasis of breast cancer cells to bone. Blood 124(20):
agonist. Proc Natl Acad Sci U S A 95(6):3082–3087, 1998. 3141–3150, 2014.
1486. Cho JR, et al: Unmet needs in the management of acute myocardial infarction: Role 1520. Siess W, et al: Lysophosphatidic acid mediates the rapid activation of platelets and
of novel protease-activated receptor-1 antagonist vorapaxar. Vasc Health Risk Manag endothelial cells by mildly oxidized low density lipoprotein and accumulates in
10:177–188, 2014. human atherosclerotic lesions. Proc Natl Acad Sci U S A 96(12):6931–6936, 1999.

Kaushansky_chapter 112_p1829-1914.indd 1908 17/09/15 3:30 pm